Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H27N3O5.ClH |
| Molecular Weight | 485.96 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.O=C1N(CC2=C1C=CC=C2OCC3=CC=C(CN4CCOCC4)C=C3)[C@H]5CCC(=O)NC5=O
InChI
InChIKey=VVHQVXXPZDALDV-BOXHHOBZSA-N
InChI=1S/C25H27N3O5.ClH/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27;/h1-7,21H,8-16H2,(H,26,29,30);1H/t21-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C25H27N3O5 |
| Molecular Weight | 449.499 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CC-220 is a potent cereblon modulating agent that displays anti-proliferative, pro-apoptotic and immunomodulatory activity on sensitive and resistant multiple myeloma cell lines. CC-220 is currently under clinical investigation for systemic lupus erythematosus and multiple myeloma as a single agent, or in combination with dexamethasone in patients who may have previously been exposed to pomalidomide. Comparable to other Cereblon-binding agents, ex vivo treatment of CC-220 on B-cells, T-cells, and monocytes leads to the degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). followed by disruption of the multiple myeloma promoting c-Myc/IRF4 axis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q96SW2 Gene ID: 51185.0 Gene Symbol: CRBN Target Organism: Homo sapiens (Human) Sources: http://www.bloodjournal.org/content/128/22/1591 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.34 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.61 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.06 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.62 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.85 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
0.3 mg single, oral dose: 0.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
52.8 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
41.9 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
49.3 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
45.4 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
43.2 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
0.3 mg single, oral dose: 0.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
45 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
78.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
153.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
255.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
40.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
38.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.4 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14.3 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.3 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
0.3 mg single, oral dose: 0.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
13.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32969202/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
32% |
single, unknown |
CC-220 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02773030
0.3 mg for 21 days of a 28-day cycle
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:19:18 GMT 2025
by
admin
on
Mon Mar 31 18:19:18 GMT 2025
|
| Record UNII |
79L3645KFI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
72793904
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
PRIMARY | |||
|
300000044588
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
PRIMARY | |||
|
DE-07
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
PRIMARY | |||
|
1560678-63-8
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
PRIMARY | |||
|
C141516
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
PRIMARY | |||
|
1560608-91-4
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
79L3645KFI
Created by
admin on Mon Mar 31 18:19:18 GMT 2025 , Edited by admin on Mon Mar 31 18:19:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |